Display options
Cite
Perreault-Micale C, Davie J, Breton B, et al. A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility. Mol Genet Genomic Med. 2015;3(4):363-73doi: 10.1002/mgg3.148.
Perreault-Micale, C., Davie, J., Breton, B., Hallam, S., & Greger, V. (2015). A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility. Molecular genetics & genomic medicine, 3(4), 363-73. https://doi.org/10.1002/mgg3.148
Perreault-Micale, Cynthia, et al. "A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility." Molecular genetics & genomic medicine vol. 3,4 (2015): 363-73. doi: https://doi.org/10.1002/mgg3.148
Perreault-Micale C, Davie J, Breton B, Hallam S, Greger V. A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility. Mol Genet Genomic Med. 2015 Jul;3(4):363-73. doi: 10.1002/mgg3.148. Epub 2015 Apr 23. PMID: 26247052; PMCID: PMC4521971.
Copy Download .nbib Format: NLM
Share it on

Mol Genet Genomic Med. 2015 Jul;3(4):363-73. doi: 10.1002/mgg3.148. Epub 2015 Apr 23.

A rigorous approach for selection of optimal variant sets for carrier screening with demonstration of clinical utility.

Molecular genetics & genomic medicine

Cynthia Perreault-Micale, Jocelyn Davie, Benjamin Breton, Stephanie Hallam, Valerie Greger

Affiliations

  1. Good Start Genetics, Inc. 237 Putnam Avenue, Cambridge, Massachusetts, 02139.

PMID: 26247052 PMCID: PMC4521971 DOI: 10.1002/mgg3.148

Abstract

Carrier screening for certain diseases is recommended by major medical and Ashkenazi Jewish (AJ) societies. Most carrier screening panels test only for common, ethnic-specific variants. However, with formerly isolated ethnic groups becoming increasingly intermixed, this approach is becoming inadequate. Our objective was to develop a rigorous process to curate all variants, for relevant genes, into a database and then apply stringent clinical validity classification criteria to each in order to retain only those with clear evidence for pathogenicity. The resulting variant set, in conjunction with next-generation DNA sequencing (NGS), then affords the capability for an ethnically diverse, comprehensive, highly specific carrier-screening assay. The clinical utility of our approach was demonstrated by screening a pan-ethnic population of 22,864 individuals for Bloom syndrome carrier status using a BLM variant panel comprised of 50 pathogenic variants. In addition to carriers of the common AJ founder variant, we identified 57 carriers of other pathogenic BLM variants. All variants reported had previously been curated and their clinical validity documented, or were of a type that met our stringent, preassigned validity criteria. Thus, it was possible to confidently report an increased number of Bloom's syndrome carriers compared to traditional, ethnicity-based screening, while not reducing the specificity of the screening due to reporting variants of unknown clinical significance.

Keywords: BLM; bloom syndrome; carrier screening; next-generation DNA sequencing; recessive disorders; variant classification

References

  1. Hum Mutat. 2011 Apr;32(4):358-68 - PubMed
  2. Genome Biol. 2014 Mar 25;15(3):R53 - PubMed
  3. J Genet Syndr Gene Ther. 2013 Sep 18;4(8):null - PubMed
  4. JAMA. 1993 Nov 17;270(19):2307-15 - PubMed
  5. J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S191-8 - PubMed
  6. Hum Mutat. 2014 Oct;35(10):1249-59 - PubMed
  7. J Mol Diagn. 2014 Mar;16(2):180-9 - PubMed
  8. Am J Hum Genet. 1995 Nov;57(5):1019-27 - PubMed
  9. Nat Genet. 2010 Nov;42(11):969-72 - PubMed
  10. Genet Med. 2005 Oct;7(8):571-83 - PubMed
  11. Mutat Res. 2005 Jun 3;573(1-2):160-7 - PubMed
  12. Int J Cancer. 2012 Jun 15;130(12):2867-73 - PubMed
  13. Nature. 2014 Apr 24;508(7497):469-76 - PubMed
  14. Genet Med. 2008 Apr;10(4):294-300 - PubMed
  15. Science. 2012 May 11;336(6082):740-3 - PubMed
  16. Genet Test. 2008 Jun;12(2):257-61 - PubMed
  17. Hum Mutat. 2007 Aug;28(8):743-53 - PubMed
  18. Clin Chem Lab Med. 2011 Aug;49(8):1289-93 - PubMed
  19. Nat Genet. 2013 Oct;45(10):1160-7 - PubMed
  20. Genet Med. 2008 Jan;10(1):57-72 - PubMed
  21. Mol Biol Cell. 1999 Mar;10(3):665-76 - PubMed
  22. Sci Transl Med. 2011 Jan 12;3(65):65ra4 - PubMed
  23. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11983-8 - PubMed
  24. Int J Mol Med. 2004 Sep;14(3):439-42 - PubMed
  25. Clin Genet. 2013 Nov;84(5):453-63 - PubMed
  26. J Cyst Fibros. 2012 Dec;11(6):511-7 - PubMed
  27. Genet Med. 2014 Feb;16(2):132-40 - PubMed
  28. Genome Biol. 2011 Sep 14;12(9):R84 - PubMed
  29. Hum Mutat. 2011 Jun;32(6):661-8 - PubMed
  30. Obstet Gynecol. 2004 Aug;104(2):425-8 - PubMed
  31. Gene. 2013 Dec 15;532(2):173-6 - PubMed
  32. Hum Mutat. 2010 Nov;31(11):1240-50 - PubMed
  33. Hum Mutat. 2008 Nov;29(11):1261-4 - PubMed

Publication Types